Middle East tensions put investors on alert, weighing worst-case scenarios
NEW YORK (Reuters) -Investors are mulling a host of different market scenarios should the U.S. deepen its involvement in the Middle East conflict, with the potential for ripple effects if energy prices skyrocket.
They have honed in on the evolving situation between Israel and Iran, which have exchanged missile strikes, and are closely monitoring whether the U.S. decides to join Israel in its bombing campaign.
Potential scenarios could send inflation higher, dampening consumer confidence and lessening the chance of near-term interest rate cuts. This would likely cause an initial selloff in equities and possible safe-haven bid for the dollar.
While U.S. crude prices have climbed some 10% over the past week, the S&P 500 has been little changed as of yet, following an initial drop when Israel launched its attacks. However, if attacks were to take out Iranian oil supply, "that's when the market is going to sit up and take notice," said Art Hogan, chief market strategist at B Riley Wealth. "If you get disruption to supply of oil product on the global marketplace, that is not reflected in today's WTI price and that is where things get negative," Hogan said. The White House said on Thursday President Donald Trump would decide on U.S. involvement in the conflict in the next two weeks. Analysts at Oxford Economics modeled three scenarios, ranging from a de-escalation in the conflict, a complete shutdown in Iranian production, and a closure of the Strait of Hormuz, "each with increasingly large impacts on global oil prices," the firm said in a note. In the most severe case, global oil prices jump to around $130 per barrel, driving U.S. inflation near 6% by the end of this year, Oxford said in the note. "Although the price shock inevitably dampens consumer spending because of the hit to real incomes, the scale of the rise in inflation and concerns about the potential for second-round inflation effects likely ruin any chance of rate cuts in the U.S. this year," Oxford said in the note.
OIL IMPACT
The biggest market impact from the escalating conflict has been restricted to oil, with oil prices soaring on worries that the Iran-Israel conflict could disrupt supplies. Brent crude futures have risen as much as 18% since June 10, hitting a near 5-month high of $79.04 on Thursday.
The accompanying rise in investors' expectations for further near-term volatility in oil prices has outpaced the rise in volatility expectations for other major asset classes, including stocks and bonds.
But other asset classes, including stocks, could still feel the knock-on effects of higher oil prices, especially if there is a larger surge in oil prices if the worst market fears of supply disruptions come true, analysts said.
"Geopolitical tensions have been mostly ignored by equities, but they are being factored into oil," Citigroup analysts wrote in a note.
"To us, the key for equities from here will come from energy commodity pricing," they said.
STOCKS UNPERTURBED
U.S. stocks have so far weathered rising Middle East tensions with little sign of panic. A more direct U.S. involvement in the conflict could, however, spook markets, investors said.
Financial markets may be in for an initial selloff if the U.S. military attacks Iran, with economists warning that a dramatic rise in oil prices could damage a global economy already strained by Trump's tariffs.
Still, any pullback in equities might be fleeting, history suggests. During past prominent instances of Middle East tensions coming to a boil, including the 2003 Iraq invasion and the 2019 attacks on Saudi oil facilities, stocks initially languished but soon recovered to trade higher in the months ahead.
On average, the S&P 500 slipped 0.3% in the three weeks following the start of conflict, but was 2.3% higher on average two months following the conflict, according to data from Wedbush Securities and CapIQ Pro.
DOLLAR WOES
An escalation in the conflict could have mixed implications for the U.S. dollar, which has tumbled this year amid worries over diminished U.S. exceptionalism.
In the event of U.S. direct engagement in the Iran-Israel War, the dollar could initially benefit from a safety bid, analysts said.
"Traders are likely to worry more about the implicit erosion of the terms of trade for Europe, the UK, and Japan, rather than the economic shock to the US, a major oil producer," Thierry Wizman, Global FX & Rates Strategist at Macquarie Group, said in a note.
But longer-term, the prospect of US-directed 'nation-building' would probably weaken the dollar, he said.
"We recall that after the attacks of 9/11, and running through the decade-long US presence in Afghanistan and Iraq, the USD weakened," Wizman said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
Cardinal Health expands urology focus with $1.9bn Solaris Health deal
US drug distributor Cardinal Health has signed a $1.9bn agreement to acquire a majority stake in Solaris Health from Lee Equity Partners. The deal aims to expand the Specialty Alliance, the distributor's multi-speciality management services organisation (MSO) platform, in which Cardinal will gain a stake of around 75%. The acquisition will also create the Urology Alliance, comprising a collaborative network of urology providers within Cardinal's Specialty Alliance MSO, as well as resonate with plans to expand the delivery of urological patient care. Cardinal's Solaris buyout complements its recent acquisitions of Urology America, Potomac Urology, and Academic Urology & Urogynaecology, signalling its urologic strategy. The transaction is expected to be completed by the end of this year, pending customary closing conditions. Cardinal Health CEO Jason Hollar stated that growing the Speciality Alliance is a 'top priority' for the company, with the latest urology purchase leaving it 'well-positioned to meet the comprehensive needs of community urologists through the robust combined capabilities of the Specialty Alliance, Specialty Networks and Cardinal Health'. Research indicates there is a shortage of urologists in the US, with 62% of US counties lacking a practising urologist and just one new urologist entering the field for every ten retiring. The figures lead to challenges in the broader field, including delayed diagnoses, increased rates of advanced-stage conditions, and significant health disparities, with these particularly pronounced in rural communities. GlobalData's senior medical analyst Selena Yu foresees Cardinal's acquisition as reflecting a shift from drug distribution with a 'lower profit margin, towards higher margin speciality care in urology'. Yu said: 'MSOs help streamline backend work like billing and staffing to allow for physicians to focus on care. 'Additionally, with a large network of specialists, patients can receive care in the same region by different care specialists, which will reduce wait times and improve care continuity. Additionally, the Cardinal Health Alliance has other specialities like oncology specialists, which makes referrals more streamlined.' Cardinal's acquisition coincided with the release of its Q4 2025 financials. The company's profits per share came in at $2.08, beating the forecasted $2.03, yet profits for the quarter came in at $60.2bn, below the $60.92bn forecast, prompting a pre-market stock drop of more than 11% on 12 August. Cardinal's share price has since recovered to a drop of around 6% to $147.05 per share, down from $157.66 per share at market close on 11 August. "Cardinal Health expands urology focus with $1.9bn Solaris Health deal" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Effettua l'accesso per consultare il tuo portafoglio
Yahoo
21 minutes ago
- Yahoo
Texas sues Eli Lilly for allegedly bribing providers to prescribe its medications
WASHINGTON (Reuters) -Texas Attorney General Ken Paxton on Tuesday sued U.S. drugmaker Eli Lilly for allegedly "bribing" providers to prescribe its medications. The attorney general's office said in a statement that the company bribed and illegally induced medical providers to prescribe its most profitable drugs, including the GLP-1 medications Mounjaro and Zepbound, used for weight loss and diabetes treatment. "Big Pharma compromised medical decision-making by engaging in an illegal kickback scheme," Attorney General Paxton said. The lawsuit builds upon Attorney General's previous legal action to hold drug manufacturers accountable for fraud and abuse, the statement added. Last year, Paxton had sued insulin manufacturers, including Lilly and pharmacy benefit managers (PBMs), alleging that manufacturers artificially raised the prices of insulin and then paid a significant, undisclosed portion back to the PBMs for preferential treatment in return. Eli Lilly did not immediately respond to a Reuters request for comment. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21 minutes ago
- Yahoo
Trump Floats Deal to Let Nvidia's Blackwell Chips Into China -- With a 50% Power Cut
President Donald Trump has signaled he may be open to letting Nvidia (NASDAQ:NVDA) ship a toned-down version of its most advanced Blackwell AI chip to China if the company trims its capabilities by 30% to 50%. The comment comes shortly after Trump confirmed an unusual arrangement already in place for Nvidia's less-powerful H20 chip, which allows exports to China in exchange for a 15% revenue share paid directly to the US government. Advanced Micro Devices will follow the same formula for its MI308 chip, according to a person familiar with the matter. Nvidia has not commented on the president's remarks. Warning! GuruFocus has detected 5 Warning Signs with NVDA. The potential deal for Blackwell would mirror Trump's broader push to secure financial returns for the US in exchange for loosening certain export restrictions a strategy that could influence how American companies negotiate market access in China. While Trump didn't outline a specific timeline, he suggested Nvidia CEO Jensen Huang could soon meet with him to discuss a negatively enhanced Blackwell variant. If approved, the move could mark a shift in how high-end US chip technology is selectively offered abroad. Nvidia's Blackwell chips are the backbone of today's most powerful AI systems but remain off-limits to China under current US rules. Both Nvidia and AMD (NASDAQ:AMD) have taken revenue hits as tighter controls limited exports to older models on par with domestic Chinese alternatives products that have struggled to gain traction. Nvidia has already said it is developing another China-specific chip and will seek approval to sell it. The company noted that further cutting back its Hopper-based H20 chip is no longer viable, suggesting a modified Blackwell could be the clearest path to regaining momentum in one of the world's largest AI markets. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data